Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04936724 · ClinicalTrials.gov registry record · NA

FDA Cigarette Warning Labels: Eye Tracking Study

A NA study of Smoking, Cigarette, sponsored by Abramson Cancer Center at Penn Medicine.

Completed
Registry status
NA
Development phase
70
Enrollment target
1
Study location

NCT04936724: Completed NA study of Smoking, Cigarette, sponsored by Abramson Cancer Center at Penn Medicine.

NCT04936724 is a NA study of Smoking, Cigarette that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 70 participants, below the 531-participant average among 21 other Smoking, Cigarette trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04936724, a NA study of Smoking, Cigarette, has completed, sponsored by Abramson Cancer Center at Penn Medicine.

COMPLETED
Registry status
NA
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine the effect of cigarette pictorial warning label content (lesser-known vs well-known risks) on visual engagement, recall, and knowledge of tobacco use harms.

Primary Outcome

We defined areas of interest (AOIs) encompassing the image and text portions of each PWL. For each AOI, we examined attention measures of latency (time until the first fixation in the AOI; i.e., how quickly attention is drawn to the AOI), latency duration (length of the first fixation; i.e., how long the AOI is initially viewed), and total fixation time (sum of all fixations in the AOI; i.e., overall viewing allocation, accounting for viewing the same AOI multiple times). Analyses examined the m

Conditions Studied

Interventions

  • OTHER Pictorial Warning Labels

Study Locations (1)

Pennsylvania

  • Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2020-12-22
Est. Completion 2021-11-19
Phase NA

What the finished NCT04936724 record still lists

NCT04936724 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 531-participant average among 21 other Smoking, Cigarette trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Smoking, Cigarette appearing as the primary indexed condition, and to 1 intervention - of which Pictorial Warning Labels is the first listed.

NCT04936724 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04936724 about?

NCT04936724 is a clinical study titled "FDA Cigarette Warning Labels: Eye Tracking Study". The purpose of this study is to examine the effect of cigarette pictorial warning label content (lesser-known vs well-known risks) on visual engagement, recall, and knowledge of tobacco use harms.

What is the current status of trial NCT04936724?

This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2020-12-22. Estimated completion is 2021-11-19.

What conditions does trial NCT04936724 study?

This clinical trial studies the following conditions: Smoking, Cigarette.

What interventions are being tested in trial NCT04936724?

The interventions under investigation include: Pictorial Warning Labels (OTHER).

Who is sponsoring clinical trial NCT04936724?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04936724 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking, Cigarette

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04936724's enrollment target sits among peer trials

70 14th of 21 higher than 8 of 21 other Smoking, Cigarette trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Smoking, Cigarette trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04936724, the US trial registry maintained by the National Library of Medicine. NCT04936724 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.